Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 2; peer review: 2 approved]

Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 2; peer review: 2 approved]

Cannabidiol (CBD)-containing products are widely marketed as over the counter products, mostly as food supplements, to avoid the strict rules of medicinal products. Side-effects reported in anecdotal consumer reports or during clinical studies were first assumed to be due to hydrolytic conversion of...

Full description

Bibliographic Details
Main Authors:	Dirk W. Lachenmeier, Stephanie Habel, Berit Fischer, Frauke Herbi, Yvonne Zerbe, Verena Bock, Tabata Rajcic de Rezende, Stephan G. Walch, Constanze Sproll
Format:	Article
Language:	English
Published:	F1000 Research Ltd 2020-02-01
Series:	F1000Research
Online Access:	https://f1000research.com/articles/8-1394/v2

Similar Items

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 4; peer review: 2 approved, 1 approved with reservations]
by: Dirk W. Lachenmeier, et al.
Published: (2021-07-01)

Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 3; peer review: 2 approved, 1 approved with reservations]
by: Dirk W. Lachenmeier, et al.
Published: (2020-08-01)

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
by: Patricia Golombek, et al.
Published: (2020-06-01)

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
by: Thomas Meyer, et al.
Published: (2019-09-01)

Study of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) extraction FROM dried oral fluid spots (DOFS) and LC–MS/MS detection
by: Roberta Gorziza, et al.
Published: (2021-07-01)

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination.
by: Katja Linher-Melville, et al.
Published: (2020-01-01)

Efficacy of Δ9 -Tetrahydrocannabinol (THC) Alone or in Combination With a 1:1 Ratio of Cannabidiol (CBD) in Reversing the Spatial Learning Deficits in Old Mice
by: Prakash Nidadavolu, et al.
Published: (2021-08-01)

Comment on Lachenmeier et al (2020) “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”: disputation on various points in the publication [version 1; peer review: 2 approved]
by: Daniel Kruse, et al.
Published: (2020-08-01)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
by: Chris M. Stauch, et al.
Published: (2020-10-01)

Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
by: Brendon J Yee, et al.
Published: (2020-05-01)

Analysis of Cannabidiol, Δ9-Tetrahydrocannabinol, and Their Acids in CBD Oil/Hemp Oil Products
by: Mahmoud A. ElSohly, et al.
Published: (2020-08-01)

Tetrahydrocannabinol (THC) cartridge ingestion
by: Logan Meyer, et al.
Published: (2020-03-01)

Evidence for adverse effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association [version 2; peer review: 2 approved]
by: Dirk W. Lachenmeier, et al.
Published: (2021-08-01)

Evidence for side effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association [version 1; peer review: 2 approved]
by: Dirk W. Lachenmeier, et al.
Published: (2020-08-01)

Medical Marijuana, CBD and THC
by: Calhoun, McKenzie L.
Published: (2019)

CBD, a precursor of THC in e-cigarettes
by: Zsuzsanna Czégény, et al.
Published: (2021-04-01)

Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
by: Marina Gabaglio, et al.
Published: (2021-08-01)

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
by: Janet Hardy, et al.
Published: (2020-07-01)

Acute human exposure assessment to tetrahydrocannabinol (Δ9‐THC)
by: European Food Safety Authority (EFSA), et al.
Published: (2020-01-01)

The Impact of THC and CBD in Schizophrenia: A Systematic Review
by: Saeed Ahmed, et al.
Published: (2021-07-01)

Understanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as Antioxidants
by: Káthia M. Honório, et al.
Published: (2013-10-01)

Towards Better Delivery of Cannabidiol (CBD)
by: Sophie Anne Millar, et al.
Published: (2020-08-01)

Detection of Δ9-tetrahydrocannabinol (THC) in hair using GC–MS
by: Himanshu Khajuria, et al.
Published: (2014-03-01)

Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging
by: Evins, A.E, et al.
Published: (2022)

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
by: Paul T. Kocis, et al.
Published: (2020-07-01)

Glucocorticoids, Stress and Delta-9 Tetrahydrocannabinol (THC) during Early Embryonic Development
by: Alexander G. Kuzma-Hunt, et al.
Published: (2021-07-01)

Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
by: Joshua D. Brown
Published: (2020-03-01)

The Diels‐Alder Approach towards Cannabinoid Derivatives and Formal Synthesis of Tetrahydrocannabinol (THC)
by: Dr. Thomas Hurrle, et al.
Published: (2021-05-01)

Does cannabidiol protect against adverse psychological effects of THC?
by: Raymond J.M. eNiesink, et al.
Published: (2013-10-01)

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC
by: Seok Hee Kim, et al.
Published: (2019-12-01)

Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101
by: Todd M. Stollenwerk, et al.
Published: (2021-09-01)

Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract
by: Joseph J. Wakshlag, et al.
Published: (2020-09-01)

Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders
by: Baswan SM, et al.
Published: (2020-12-01)

Cannabidiol (CBD) as a Promising Anti-Cancer Drug
by: Emily S. Seltzer, et al.
Published: (2020-10-01)

Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function.
by: Matthijs G Bossong, et al.
Published: (2013-01-01)

Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review
by: Lourdes Poyatos, et al.
Published: (2020-06-01)

Suppression of STAT3 Signaling by Δ9-Tetrahydrocannabinol (THC) Induces Trophoblast Dysfunction
by: Xinwen Chang, et al.
Published: (2017-06-01)

Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses <it>in vitro</it>
by: Friedman Herman, et al.
Published: (2004-09-01)

Cannabis, Cannabidiol Oils and Tetrahydrocannabinol—What Do Veterinarians Need to Know?
by: Nancy De Briyne, et al.
Published: (2021-03-01)

Availability and Promotion of Cannabidiol (CBD) Products in Online Vape Shops
by: Eric C. Leas, et al.
Published: (2021-06-01)